Skip to search formSkip to main contentSkip to account menu

NSC 336628

Known as: NSC-336628 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

merbarone

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Evaluation of merbarone (NSC 336628) in disseminated malignant melanoma
Merbarone, NSC 336628, is an investigational anticancer drug with activity against experimental animal tumors including melanoma… 
1996
1996
A phase II trial of merbarone (NSC 336628) in the treatment of recurrent epithelial ovarian carcinoma. A Gynecologic Oncology Group Study.
BACKGROUND Patients with recurrent epithelial ovarian carcinoma who progress through a cisplatin-based regimen or recur less than… 
1995
1995
A Phase II Trial of Merbarone (NSC 336628) as Salvage Therapy for Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study
Twenty-seven patients with previously irradiated unresectable recurrent squamous carcinoma of the cervix who had failed one prior… 
1994
1994
Phase II study of merbarone (NSC 336628) in patients with advanced gastric carcinoma.
Merbarone, 5-(N-phenylcarboxamido)-2-thiobarbituric acid (NSC 336628), is a derivative of barbituric acid and represents a unique… 
1985
1985
5-(N-phenylcarboxamido)-2-thiobarbituric acid (NSC 336628), a novel potential antitumor agent.
1985
1985
Initial mechanistic studies with merbarone (NSC 336628).
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)